Abstract:The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause for the ongoing global public health emergency. It is more commonly known as coronavirus disease 2019 (COVID-19); the pandemic threat continues to spread aroundthe world with the fluctuating emergence of its new variants. The severity of COVID-19 ranges from asymptomatic to serious acute respiratory distress syndrome (ARDS), which has led to a high human mortality rate and disruption of socioeconomic well-being. For the restoration of pre-pandemic normalcy, the international scientific community has been conducting research on a war footing to limit extremely pathogenic COVID-19 through diagnosis, treatment, and immunization. Since the first report of COVID-19 viral infection, an array of laboratory-based and point-of-care (POC) approaches have emerged for diagnosing and understanding its status of outbreak. The RT-PCR-based viral nucleic acid test (NAT) is one of the rapidly developed and most used COVID-19 detection approaches. Notably, the current forbidding status of COVID-19 requires the development of safe, targeted vaccines/vaccine injections (shots) that can reduce its associated morbidity and mortality. Massive and accelerated vaccination campaigns would be the most effective and ultimate hope to end the COVID-19 pandemic. Since the SARS-CoV-2 virus outbreak, emerging biotechnologies and their multidisciplinary approaches have accelerated the understanding of molecular details as well as the development of a wide range of diagnostics and potential vaccine candidates, which are indispensable to combating the highly contagious COVID-19. Several vaccine candidates have completed phase III clinical studies and are reported to be effective in immunizing against COVID-19 after their rollout via emergency use authorization (EUA). However, optimizing the type of vaccine candidates and its route of delivery that works best to control viral spread is crucial to face the threatening variants expected to emerge over time. In conclusion, the insights of this review would facilitate the development of more likely diagnostics and ideal vaccines for the global control of COVID-19.

Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms

COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development

Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus

Next-generation COVID-19 Vaccines: Opportunities for Vaccine Development and Challenges in Tackling COVID-19

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

COVID-19 vaccine development and a potential nanomaterial path forward

An overview of vaccine development for COVID-19

COVID-19 vaccine: where are we now and where should we go?

COVID‐19 vaccine: recent advancements and future prospects

Advanced Materials for SARS‐CoV‐2 Vaccines

A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines

Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform

Advances in gene-based vaccine platforms to address the COVID-19 pandemic

Recent advances in vaccine and immunotherapy for COVID-19

Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development

Challenges and Recent Advancements in COVID-19 Vaccines

Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms

Status Report on COVID-19 Vaccines Development

COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines

Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review

Platforms Exploited for SARS-CoV-2 Vaccine Development